By Lina carolina 
The relentless progression of cancer, characterized by its ability to invade distant organs and establish secondary growths, remains one of the most formidable challenges in modern medicine. For millions worldwide, the dreaded formation of metastases signifies a dire prognosis, underscoring the critical need for novel therapeutic strategies. A groundbreaking study, recently unveiled in the esteemed journal Nature Medicine, offers a beacon of hope by demonstrating the potential of a repurposed drug, digoxin, to significantly weaken clusters of circulating tumor cells (CTCs), thereby reducing the risk of metastatic spread, particularly in breast cancer. This research, a testament to collaborative innovation between leading academic institutions and hospitals, illuminates a new avenue in the fight against a disease that claims millions of lives annually.
The insidious nature of metastatic cancer lies in its ability to circumvent the body’s natural defenses. Primary tumors, the initial sites of cancer development, are not static entities. They continuously shed malignant cells into the bloodstream, a process that can lead to the formation of CTCs. These rogue cells, often traveling in isolation or, as recent research highlights, in cohesive groups, can navigate the circulatory system and find fertile ground in distant organs. Here, they can seed new tumors, known as metastases, which are responsible for the vast majority of cancer-related deaths. Globally, an estimated seven million individuals succumb to metastatic disease each year, a stark statistic that fuels the urgent quest for effective interventions.
The Devastating Impact of Metastatic Breast Cancer
Breast cancer serves as a poignant example of the destructive potential of metastatic disease. While advancements in early detection and treatment have improved survival rates for localized breast cancer, the emergence of metastases dramatically alters the patient’s outlook. For tens of thousands of women each year, metastatic breast cancer represents a terminal diagnosis, highlighting the critical unmet need for therapies that can prevent or impede this life-threatening spread. Oncologists have long sought ways to disarm these circulating tumor cell clusters, recognizing them as key drivers of metastatic progression.
A Novel Therapeutic Approach Emerges
The recent study, conducted by a multidisciplinary team from ETH Zurich, the University Hospitals of Basel and Zurich, and the Basel-Land Cantonal Hospital, has introduced a promising new strategy. Their clinical investigation focused on the drug digoxin, a compound historically used to treat heart conditions. Administered at a low, safe dosage for a one-week period to nine patients battling metastatic breast cancer, the treatment yielded remarkable results. The study revealed a statistically significant reduction in the number of cells within CTC clusters, with an average decrease of 2.2 cells per cluster. Considering that these clusters often comprise only a handful of cells, this reduction represents a substantial disruption of their metastatic potential.
Professor Nicola Aceto, the principal investigator and a Professor of Molecular Oncology at ETH Zurich, elaborated on the significance of these findings. "Breast cancer metastasis depends on CTC clusters," he stated. "The larger they are, the more successful they are." This observation underscores the critical role of cluster integrity in the metastatic cascade. By weakening these cellular aggregates, the researchers aim to diminish their capacity to establish new tumors.
Unveiling the Molecular Mechanism of Action
The Achilles’ heel of CTC clusters, as identified by the research team, lies in the sodium-potassium pumps (Na+/K+-ATPases) embedded within their cell membranes. These vital protein complexes are responsible for maintaining the electrochemical gradient across the cell membrane by actively transporting sodium ions out of the cell and potassium ions into it. Digoxin, a cardiac glycoside, exerts its effect by blocking these ion pumps. This blockade disrupts the delicate balance of ion exchange, leading to an influx of calcium ions into the tumor cells. The increased intracellular calcium concentration then weakens the adhesive forces that bind the cancer cells together within the cluster, causing them to dissociate.
It is crucial to note that digoxin, in this context, does not directly eliminate existing tumors. Instead, its primary role is to disaggregate the CTC clusters, thereby preventing their successful colonization of distant organs. For a comprehensive therapeutic strategy, digoxin would likely need to be administered in conjunction with other agents designed to eradicate established cancer cells.
A Journey of Discovery: From Screening to Clinical Trials
The path to this promising discovery was paved with extensive research and a systematic approach to drug discovery. Digoxin, derived from the foxglove plant (Digitalis sp.), has a long-standing history in medicine, primarily for its efficacy in managing heart failure and other cardiac arrhythmias. However, the ETH Zurich researchers’ exploration into its potential anti-cancer properties began in 2019. At that time, they embarked on an ambitious screening program, meticulously testing over 2,400 different chemical substances in cell cultures. Their objective was to identify compounds capable of effectively targeting and disrupting clusters of circulating tumor cells. This comprehensive screening effort ultimately pinpointed digoxin as a potent candidate.
The subsequent transition from laboratory findings to clinical application involved a robust, multi-institutional collaboration. The University Hospitals of Basel and Zurich, along with the Basel-Land Cantonal Hospital, played an indispensable role in recruiting patients and facilitating the clinical trials. This seamless integration of academic research with clinical expertise was paramount to the successful execution of the study.
Future Directions and Broader Implications
The current findings represent a significant leap forward, but the research is far from complete. The ETH Zurich team is actively engaged in developing novel molecules inspired by digoxin. The goal is to create next-generation agents that exhibit enhanced efficacy in dissolving CTC clusters. This endeavor is being spearheaded by Page Therapeutics, an ETH spin-off dedicated to translating cutting-edge scientific discoveries into therapeutic realities.
Beyond breast cancer, Professor Aceto’s vision extends to other aggressive cancer types known for their propensity to metastasize. His team has initiated preliminary laboratory experiments to investigate the applicability of their approach to cancers such as prostate, colorectal, pancreatic cancer, and melanoma. If successful, this research could have a profound impact on the treatment paradigms for a wide spectrum of advanced malignancies.
A Model of Collaborative Excellence
The success of this study serves as a powerful testament to the strength of interdisciplinary and inter-institutional collaboration. The synergy between ETH Zurich’s pioneering research capabilities and the clinical acumen of the University Hospitals of Basel and Zurich, and the Basel-Land Cantonal Hospital, exemplifies a model for future translational research. This partnership ensured that laboratory breakthroughs could be rapidly translated into tangible patient benefits, a critical step in the arduous journey from discovery to widespread clinical adoption. The rigorous methodology, the commitment to patient safety, and the objective reporting of results in Nature Medicine further solidify the scientific merit and potential impact of this groundbreaking work. The ongoing efforts to refine digoxin-based therapies and expand their application to other cancer types offer a compelling vision for a future where metastatic disease can be more effectively controlled, offering renewed hope to millions affected by this devastating illness.